Table 2.
Intervention, interventional group characteristics, and duration of studies exploring the efficacy of SGLT-2 inhibitors in patients with concurrent type 2 diabetes mellitus and non-alcoholic fatty liver disease.
| Study | Intervention | Interventional group characteristics | Duration |
|---|---|---|---|
| Eriksson et al., (41) | Dapagliflozin | Type 2 diabetes, aged 40–75 years, BMI 25–40 kg/m2 | 12 weeks |
| Gautam et al., (80) | Canagliflozin | NAFLD, type 2 diabetes, abnormal LFT | 6 months |
| Ohki et al., (78) | Ipragliflozin | NAFLD and type 2 diabetes | Median 320 days |
| Ito et al., (42) | Ipragliflozin | NAFLD and type 2 diabetes | 24 weeks |
| Shibuya et al., (79) | Luseogliflozin | NAFLD and type 2 diabetes, aged 47–62 years, BMI 26.2–28.7 kg/m2 | Median 5 weeks |
| Seko et al., (74) | Ipragliflozin, Canagliflozin | NAFLD and type 2 diabetes | 12 weeks |
| Kuchay et al., (34) | Empagliflozin | NAFLD and type 2 diabetes, aged >20 years | 20 weeks |
BMI, body mass index; LFT, liver function test; NAFLD, non-alcoholic fatty liver disease; SGLT-2, sodium-glucose transport protein 2.